I'm on semaglutide for weight management. Should I be worried about muscle loss?

Current evidence suggests the body composition changes with GLP-1 medications are proportional to other effective weight-loss methods — not disproportionately worse. The more important question is whether your physical function is being maintained, which in trials has generally been the case. Discuss your individual situation with your GP, particularly if you have concerns about your baseline muscle health or are in perimenopause or older age.

What can I do to protect muscle while on a GLP-1 medication?

Adequate protein intake and regular resistance exercise are the two most evidence-supported strategies for maintaining muscle mass and function during any significant weight-loss program. Your GP or a dietitian can advise on targets appropriate for your age and health status.

GLP-1 weight-loss drugs and muscle: sorting signal from noise

What just happened

Social media has spent the past two years running a parallel clinical commentary on GLP-1 medications — and the muscle-loss claim has become one of its loudest recurring features. You’ve probably seen the posts: before-and-after body composition scans, fitness influencers warning that semaglutide is “eating muscle,” clinicians on Instagram drawing alarming conclusions from selected data. If you’re using or considering a GLP-1 receptor agonist for weight management and you’ve come across this content, that content can leave a person genuinely alarmed.

This week, an Australian endocrinologist offered a different lens. Associate Professor Priya Sumithran from Bayside Health and Monash University presented findings at the International Diabetes Federation Western Pacific Region Congress, and the central message was measured: when GLP-1-related fat-free mass loss is placed alongside equivalent numbers from bariatric surgery and intensive behavioural programs, it doesn’t appear to be an outlier.

That contextual shift is the most clinically meaningful thing to take from this. The question was never whether body composition changes during GLP-1 treatment — it does, as it does during every effective weight-loss program. The question is whether the changes are disproportionate. On current evidence, they are not.

The both-and

What “muscle loss” actually measures — and what it doesn’t

The first thing Sumithran clarified is terminological, and it matters more than it sounds: fat-free mass is not the same as skeletal muscle. Fat-free mass is everything that isn’t fat — muscle tissue, yes, but also bone, connective tissue, organ mass, and body water. Different measurement tools — DEXA, CT, and MRI — capture different fractions of that pool. Comparing “fat-free mass loss” across studies that use different methods is, at best, imprecise.

Historical data shows that weight-loss programs of all kinds produce roughly 25% fat-free mass loss as a proportion of total weight lost. GLP-1 studies fall between 29–39% — somewhat higher than that baseline, but within the same range as bariatric surgery (31–44%) and intensive behavioural programs (26–38%). GLP-1 medications sit in a comparable position to every other effective weight-reduction intervention, not above it.

A landmark 2024 systematic review found that skeletal muscle changes after GLP-1 treatment appeared adaptive — proportional to age, disease status, and the amount of weight lost — rather than evidence of pathological wasting. Glucose uptake and disposal improved even as muscle volume reduced, suggesting the metabolic story is considerably more nuanced than a simple “less muscle” reading allows.

Where the uncertainty remains

This is not a clean all-clear, and Sumithran was careful in saying so. Robust long-term data on objective muscle strength and physical function from GLP-1 treatment remains limited. Most trials have used self-reported physical function — useful evidence, but not the same as grip strength measurements, chair-rise speed, or six-minute walk data over five to ten years. High-quality studies focused specifically on objective strength outcomes over the long term are still pending.

There are also population subgroups for whom the question is sharper than the trial averages suggest. An older adult with established sarcopenia — already operating with reduced muscle reserve — is in a meaningfully different position from a 38-year-old with metabolic obesity and full functional capacity. Women in perimenopause, when oestrogen-driven muscle changes are already in motion, have a different physiological starting point than the average trial participant. These subgroups are underrepresented in the existing data.

The practical clinical response to this uncertainty is not to avoid GLP-1 medications in suitable candidates — it’s to attend carefully to nutrition and resistance exercise alongside the pharmacological program. Sumithran’s clinical recommendation included adequate protein intake and resistance training during the weight-loss phase — not GLP-1-specific advice, but sound practice during any significant weight-reduction effort.

The muscle-loss narrative online has outrun the evidence, and it is having real consequences. People who might benefit from effective weight management — people carrying elevated cardiovascular risk, poorly controlled type 2 diabetes, metabolic-associated steatohepatitis, or significant obstructive sleep apnoea — are making avoidance decisions based on content that presents selected data without comparison groups.

A reduction in fat-free mass sounds alarming as a standalone number. Placed alongside equivalent figures from bariatric surgery or intensive diet programs, it becomes a proportional finding in a different light entirely. GPs are increasingly the first people patients bring these concerns to, and being able to contextualise the numbers — rather than dismissing the concern — is now part of managing these medications.

My two cents

If you are on a GLP-1 medication and the muscle-loss question has come up in something you’ve read: bring it to your GP rather than quietly stopping your medication. The clinical picture is more reassuring than the social media version — but your individual situation, including your baseline muscle health, age, diet, and activity level, is what actually determines the relevant risk.

If you’re considering a GLP-1 medication for weight management, ask your GP specifically about protein intake and resistance exercise alongside the pharmacological treatment. Not because the muscle-loss concern is confirmed — it isn’t — but because optimising body composition during significant weight loss is sound clinical practice regardless of method.

Verdict: maybe — the proportionality finding is reassuring, but long-term objective muscle function data is still pending; discuss with your GP if this concern is on your radar.

Sources cited

Should we be concerned about muscle loss with GLP-1 medications? — Medical Republic, September 7, 2026. https://www.medicalrepublic.com.au/should-we-be-concerned-about-muscle-loss-with-glp-1-medications/128767